Follow the progress of Hemolens Diagnostics
This website contains information intended only for persons professionally dealing with medical devices (e.g. for persons performing medical professions, for persons dealing with the distribution of medical devices). Please confirm that you are a medical device professional to proceed.
Follow the progress of Hemolens Diagnostics
August 8, 2022
Coronary artery disease has been the leading cause of death worldwide for many years. Therefore, work on innovative, non-invasive diagnostics of CAD in Hemolens has been ongoing for over 7 years. This is a good time to sum up.
2015 – We started our mission by creating technology for personalized, non-invasive and precise diagnostics to reduce invasive procedures in healthcare.
2018 – Start of clinical trials and start of the cooperation with Microsoft. First patent applications filed.
2019 – Our diagnostic system received the CE Certificate.
2021 – We performed the first PMS (Post Marketing Studies) clinical trials and started Hemolens Diagnostics B.V. in the Netherlands.
2022 – We focused on the comfort of employees and moved the company’s headquarters to a new location. You can find us now in the Business Garden complex at Legnicka Street 48G in Wrocław.
Since 2015, we have been developing a non-invasive diagnostics method of coronary heart disease. We believe in innovative medicine that, thanks to technology based on computational fluid dynamics (CFD) and artificial intelligence (AI), is evolving from invasive procedures to more precise, safe and patient-friendly methods of diagnostics and treatment.
Thanks to the cooperation with doctors and specialists in various fields and proprietary technology, we want a new standard in the diagnosis of CAD to be available in medical centres and around the world.
